Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.70 |
| ▸ | DRD2 | P14416 | 2/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5986956 | 0.89 | DRD4 (0.77) | DRD4DRD2DRD3SIGMAR1HTR1A | |
| SCHEMBL27662780 | 0.87 | AGXT (0.56) | DRD4DRD2DRD3PRMT6SIGMAR1 | |
| SCHEMBL2660374 | 0.86 | DRD4 (0.72) | DRD4DRD2DRD3SIGMAR1ITGB3 | |
| SCHEMBL13637639 | 0.85 | ALDH1A1 (0.65) | DRD4DRD2DRD3PRMT6HTR7 | |
| SCHEMBL6031812 | 0.83 | DRD4 (1.00) | DRD4DRD2DRD3SIGMAR1HTR1A | |
| SCHEMBL2376462 | 0.83 | CHRNA7 (0.59) | DRD4DRD2DRD3PRMT6KDM4E | |
| SCHEMBL9374413 | 0.83 | SIGMAR1 (0.76) | DRD4DRD2DRD3SIGMAR1HTR1A | |
| SCHEMBL13902706 | 0.81 | DRD2 (1.00) | DRD4DRD2DRD3HTR7ALDH1A1 | |
| SCHEMBL30643008 | 0.81 | DRD4 (0.70) | DRD4DRD2DRD3SIGMAR1HTR1A | |
| SCHEMBL29132943 | 0.81 | DRD4 (0.70) | DRD4DRD2DRD3SIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590329-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2005-11-02 | — | — | EP | disclosed |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-06-16 | — | — | US | disclosed |
| WO-2004078732-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AHR, NQO1, ARNT | DRD4 2278/4885DRD2 1957/4885DRD3 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.